PON1, paraoxonase 1, 5444

N. diseases: 496; N. variants: 29
Disease: Anemia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002871
Disease: Anemia
Anemia 		0.040 Biomarker disease BEFREE Personalized Anemia Management and Precision Medicine in ESA and Iron Pharmacology in End-Stage Kidney Disease. 30082060 2018
CUI: C0002871
Disease: Anemia
Anemia 		0.040 Biomarker disease BEFREE The objective of the study was to examine overall anemia management trends in non-dialysis patients with chronic kidney disease (CKD) from 2006 to 2015, and to evaluate the impact of Trial to Reduced Cardiovascular Events with Ananesp Therapy (TREAT)'s study results (October 2009) and the US Food and Drug Administration (FDA)'s (June 2011) safety warnings and guidelines on the use of ESA therapy in the current treatment of anemia. 30413150 2018
CUI: C0002871
Disease: Anemia
Anemia 		0.040 AlteredExpression disease BEFREE Decrease in PON1 activity is associated with the degree of oxidative stress, anaemia and increase in CIMT. 21427447 2011
CUI: C0002871
Disease: Anemia
Anemia 		0.040 AlteredExpression disease LHGDN PON1's arylesterase activity reflected anemia severity, being correlated with hemoglobin, hematocrit, and iron. 18423402 2008